ScholarWorks@SOONCHUNHYANG UNIVERSITY: Jeong, Soung Won

Detailed Information

Jeong, Soung Won (정승원)

College of Medicine (Department of Internal Medicine)

Research Area

Tel
E-mail
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

hepatocellular carcinoma:10||Liver cirrhosis:9||Carcinoma:6||hepatocellular:6||Hepatocellular carcinoma:6||liver cirrhosis:5||Diagnosis:5||chronic hepatitis B:4||Prognosis:4||Chronic hepatitis C:4||survival:4||Cirrhosis:4||Hepatitis B virus:4||Transient elastography:3||Hepatic venous pressure gradient:3||Nonalcoholic fatty liver disease:3||NA:3||Recurrence:3||prognosis:3||Elasticity imaging techniques:3||Treatment:3||Esophageal and gastric varices:3||acute decompensation:3||acuteonchronic liver failure:3||Variceal bleeding:2||Nonselective βblocker:2||GGT:2||Chemoembolization:2||hepatitis B:2||Viral hepatitis:2||Hepatitis B:2||소화기내과:2||Hepatitis C virus:2||Liver Cirrhosis:2||의약학:2||Portal hypertension:2||Gastroesophageal varices:2||liver transplantation:2||Liver stiffness:2||Liver transplantation:2||mortality:2||Antiviral therapy:2||nonalcoholic fatty liver disease:2||Survival:2||Sustained virologic response:2||antiviral therapy:2||Endoscopic variceal ligation:2||Endosonography:2||Tenofovir:2||chronic:2||HBV:2||Fibrosis:2||Autoimmune hepatitis:2||Epidemiology:2||HVPG:2||risk prediction:2||cystatin C:2||Hepatic encephalopathy:2||Ultrasonography:2||End hole catheter measurement:1||Endoscopic grade of esophageal varices:1||Entecavir:1||Esophageal adenocarcinoma:1||Esophageal varices:1||Etiology:1||Extrahepatic metastases:1||F18fluorodeoxyglucose positron emission tomography/computed tomography scan:1||Fatty liver:1||Feeding artery:1||Fibroscan:1||Fibroscan 630:1||Fluorodeoxyglucose F18:1||Focal liver lesions (FLLs):1||Functional cure:1||Fundal varices:1||Gastric variceal bleeding:1||Gastric varices:1||Gastric varix:1||Gastrointestinal hemorrhage:1||Glomerular Filtration Rate:1||Glucosamine:1||Guideline:1||Guidelines:1||HBV DNA:1||HBcrAg:1||HCC:1||Hematochezia:1||Hemorrhage:1||Hepatic venous pressure gradient (HVPG):1||Hepatitis:1||Hepatitis C:1||Hepatopulmonary syndrome:1||Hepatotoxicity:1||Histoacryl:1||Histoacryl (R) (Nbutyl2cyanoacrylate):1||Histoacryl (R) injection:1||Hypertension, Portal:1||Hypertension, portal:1||Immune system:1||Immunohistochemistry:1||Incidence:1||Insulin resistance:1||Interferongamma:1||Interferonα2b:1||International:1||Jaundice:1||Jejunal Varices:1||Korea:1||Koreans:1||Lamivudine resistance:1||Lipid metabolism:1||Lipopolysaccharide:1||Liver Cancer:1||Liver fibrosis:1||Liver injury:1||Liver masses:1||Maddrey's discriminant function:1||Magnifying endoscopy:1||Management:1||Methylene blue chromoendoscopy:1||Minimal Hepatic Encephalopathy:1||Molecular:1||Mortality:1||Multicenter:1||Muscle mass:1||Mutation:1||N&#8208:1||NL ration in HCC:1||Natural history:1||Neutrophil:1||Occult infection:1||Organ failure:1||Overestimation:1||Overlap syndrome:1||PIVKAII:1||Pancreas:1||Patients with liver cirrhosis and hepatocellular carcinoma (HCC) are often ineligible for resection or local ablation therapy due to poor liver:1||Pegylated interferon alpha2b:1||Plants, Medicinal:1||Portal vein:1||Portasystemic shunt, surgical:1||Positronemission tomography:1||Precipitating factor:1||Precision medicine:1||Prediction:1||Predictor:1||Prescribed Medicines:1||Primary biliary cirrhosis:1||Prophylaxis:1||Psychometric Test:1||ROC curve:1||Radiationinduced liver disease:1||Randomized controlled trials as topic:1||Realtime elastography:1||Rebleeding:1||Relapse:1||Remission:1||Renal Function:1||Response:1||Restriction fragment mass polymorphism:1||Ribavirin:1||Risk Factor:1||Secondary prevention:1||Sequential organ failure assessment:1||Serum Creatinine Level:1||Sex:1||Shortsegment:1||Sodium:1||Sorafenib:1||South Korea:1||Specialized intestinal metaplasia:1||Spleen stiffness:1||Spontaneous Bacterial Peritonitis:1||Stereotactic body radiation therapy:1||Stroop test:1||Surveillance:1||Sustained virological response:1||Tcell:1||TDF:1||TRAIL Enhances Apoptosis of Human HepatocellularCarcinoma Cells Sensitized by Hepatitis C Virus Infection:Therapeutic Implications:1||Therapeutic:1||Therapeutics:1||Thrombosis:1||Tolllike receptor 9:1||Tomography:1||Toxic hepatitis:1||Traditional Therapy:1||Transarterial chemoembolization:1||Treatment of gastric varix:1||Tumor size:1||Ursodeoxycholic acid:1||Variceal hemorrhage:1||Varices:1||Vascular endothelial growth factor:1||Vasopressor:1||Virologic Response:1||Virologic response:1||Vitamin D:1||VogtKoyanagiHarada disease:1||Xray computed:1||acetyl&#8208:1||acute:1||adverse outcomes:1||aetiology:1||alcoholic:1||alcoholic hepatitis:1||alphafetoprotein:1||alternative treatment:1||antigen:1||antiviral:1||antiviral agent:1||antiviral selection:1||ascites:1||associated lipocalin:1||beta blocker:1||chemoembolization:1||chronic liver disease:1||chronic liver failure:1||cirrhosis:1||coffee:1||cohort:1||combination:1||combination therapy:1||creatinine:1||decompensated cirrhosis:1||decompensation:1||deep neural networking:1||diagnostic value:1||directacting antivirals:1||endstage liver disease:1||endoscopic variceal ligation:1||enhanced ultrasonography:1||fibrosis:1||health education:1||hepatic arterial infusion chemotherapy:1||hepatitis B e antigen:1||hepatitis B virus:1||hepatorenal syndrome:1||high cost:1||hyperlipidemia:1||immunosuppressant:1||inverse probability treatment weighting:1||kidney injury:1||liver:1||liver cancer:1||liver failure:1||liver fibrosis:1||liver stiffness:1||lowMELD:1||metabolic dysfunctionassociated steatotic liver disease:1||molecular target agents:1||neutrophil gelatinase&#8208:1||nonalcoholic steatohepatitis:1||noninferiority:1||nutrition:1||nutrition education:1||organ failure:1||performance:1||platelettowhite blood cell ratio:1||posttreatment:1||prediction model:1||qSOFA:1||radiofrequency ablation:1||random survival forests:1||reactivation:1||refractoriness:1||renal dysfunction:1||renal function:1||renal insufficiency:1||sorafenib:1||stereotactic body radiotherapy:1||survival rate:1||tenofovir:1||tenofovir disoproxil orotate:1||therapeutic:1||transarterial chemoembolization:1||transient elastography:1||treatment:1||validation:1||간 손상:1||간경변:1||글루코사민:1||내시경 정맥류 결찰술:1||독성 간염:1||리비탈:1||바이러스반응:1||비선택적 베타차단제:1||식도위정맥류:1||알라닌아미노전달효소:1||약제 내성:1||약제유발성 자가면역 간염:1||우루사:1||위식도정맥류:1||위장관출혈:1||자가면역 간염:1||치료:1||&#8208:1||테노포비어:1||&#946:1||25Hydroxyvitamin D deficiency:1||AFP:1||AFPL3:1||ALSL1023:1||Abdominal Computed Tomography:1||Acousticradiationforce impulse elastography:1||Acuteon:1||Acuteonchronic liver failure:1||Adrenal abscesses:1||Alanine aminotransferase:1||Alcoholic hepatitis:1||Alcohols:1||Another Face of ContrastEnhanced Ultrasonography: A Diagnostic Tool for Cirrhosis:1||Antiviral Therapy:1||Asia pacific:1||Bacterial translocation:1||Balloon catheter measurement:1||Barrett's esophagus:1||Betablocker:1||Biochemical Response:1||Biomarkers:1||Biphenyl dimethyl dicarboxylate:1||Blood platelets:1||B형간염:1||Capsule Endoscopy:1||Carcinoma, hepatocellular:1||Carnitine:1||ChildPugh score:1||Chronic hepatitis:1||Chronic hepatitis B:1||Circulating tumor DNA:1||Cognitive Function:1||Comparative effectiveness:1||Complete Response:1||Complete response:1||Contrast:1||Contrast enhanced Ultrasonography (CEUS):1||Contrast enhanced ultrasonography:1||Crude incidence rate:1||Cyclooxygenase 2:1||Cyclooxygenase2:1||D glucosaminidase:1||Death:1||Deterioration:1||Diabetes mellitus:1||Direct Comparison:1||Discontinuation:1||Disease progression:1||Drug induced autoimmune hepatitis:1||Drug resistance:1||Drug therapy:1||Druginduced Liver Injury:1||Druginduced liver injury:1||Dysplasia:1||ETV:1||Elastography:1||Embolization:1||

RSS_1.0 RSS_2.0 ATOM_1.0

(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE